gemfibrozil has been researched along with Complications of Diabetes Mellitus in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind, randomized crossover study, 29 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipoproteinemia were treated with gemfibrozil (1,200 mg/d) or simvastatin (10 mg/d) for 4 months." | 9.08 | A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. ( Johansson, J; Lithell, H; Ohrvall, M; Vessby, B, 1995) |
| "In a double-blind, randomized crossover study, 29 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipoproteinemia were treated with gemfibrozil (1,200 mg/d) or simvastatin (10 mg/d) for 4 months." | 5.08 | A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. ( Johansson, J; Lithell, H; Ohrvall, M; Vessby, B, 1995) |
| " The three groups were similar for age, sex and geographical region, but significantly more patients on bezafibrate had diabetes and/or hypertension than those on gemfibrozil or simvastatin." | 3.70 | A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). ( Beggs, PW; Clark, DW; Coulter, DM; Williams, SM, 1999) |
| "A retrospective chart analysis of 200 consecutive, cyclosporine-treated, renal allograft recipients, transplanted between January 1988 and June 1992, was conducted to determine the incidence of and the etiologic variables for post-transplant hypercholesterolemia." | 3.69 | Post-transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy. ( Aridge, D; Bastani, B; Garvin, PJ; Heisler, T; Lindsey, L; Puntney, G; Robinson, S; Solomon, H, 1995) |
| "Patients with a diagnosis of type 2 diabetes and either a history of coronary artery disease or at least one other significant cardiovascular risk factor as defined by the American College of Physicians guidelines (i." | 1.34 | Use of statins and gemfibrozil in patients with type 2 diabetes mellitus and cardiovascular risk factors attending adult day health care centers: an opportunity for pharmacists. ( McGuire, H; Nathan, JP; Rosenberg, JM; Zerilli, T, 2007) |
| "A 61-year-old woman with hyperlipidemia was treated with gemfibrozil." | 1.29 | [Gemfibrozil-induced myopathy]. ( Adler, Y; Aron, A; Weiss, P, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, CY | 1 |
| Huang, KH | 1 |
| Lin, CC | 1 |
| Tsai, TH | 1 |
| Shih, HC | 1 |
| Angulo, P | 1 |
| Tai, ES | 1 |
| Collins, D | 1 |
| Robins, SJ | 1 |
| O'Connor, JJ | 1 |
| Bloomfield, HE | 1 |
| Ordovas, JM | 1 |
| Schaefer, EJ | 1 |
| Brousseau, ME | 1 |
| Patel, J | 1 |
| Rosenberg, JM | 1 |
| Zerilli, T | 1 |
| Nathan, JP | 1 |
| McGuire, H | 1 |
| Bastani, B | 1 |
| Robinson, S | 1 |
| Heisler, T | 1 |
| Puntney, G | 1 |
| Aridge, D | 1 |
| Lindsey, L | 1 |
| Solomon, H | 1 |
| Garvin, PJ | 1 |
| Ohrvall, M | 1 |
| Lithell, H | 1 |
| Johansson, J | 1 |
| Vessby, B | 1 |
| Aron, A | 1 |
| Adler, Y | 1 |
| Weiss, P | 1 |
| Beggs, PW | 1 |
| Clark, DW | 1 |
| Williams, SM | 1 |
| Coulter, DM | 1 |
| Bergemann, R | 1 |
| Brandt, A | 1 |
| Siegrist, W | 1 |
2 reviews available for gemfibrozil and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Current best treatment for non-alcoholic fatty liver disease.
Topics: Antioxidants; Chromans; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Fatty L | 2003 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; D | 2006 |
2 trials available for gemfibrozil and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).
Topics: Alleles; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Gemfi | 2006 |
A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.
Topics: Aged; Body Weight; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Gemfibroz | 1995 |
6 other studies available for gemfibrozil and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates.
Topics: Adult; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Female; Fenofibrate; Gemfibrozil; H | 2012 |
Use of statins and gemfibrozil in patients with type 2 diabetes mellitus and cardiovascular risk factors attending adult day health care centers: an opportunity for pharmacists.
Topics: Ambulatory Care; Day Care, Medical; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gemfi | 2007 |
Post-transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy.
Topics: Adult; Age Factors; Black People; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Cholester | 1995 |
[Gemfibrozil-induced myopathy].
Topics: Diabetes Complications; Female; Gemfibrozil; Humans; Hyperlipidemias; Kidney Failure, Chronic; Middl | 1993 |
A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Topics: Bezafibrate; Cohort Studies; Comorbidity; Diabetes Complications; Female; Gemfibrozil; Humans; Hyper | 1999 |
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperl | 1993 |